Haemophilus b Conjugate Vaccine

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Conditions

DysenteryDysentery, BacillaryHIV InfectionsHealthy Volunteers (Meningococcal Infection)

Phase 2

Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old

CompletedNCT04865497

Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdDysentery, Dysentery, Bacillary

Start: 2019-01-19End: 2020-12-31Updated: 2022-01-13

Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

CompletedNCT03691610

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2018-10-04End: 2023-10-20Updated: 2024-06-25

Unknown Phase

Study of Anti-HIV Therapy Intensification

CompletedNCT00034086

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2006-06-30Target: 22Updated: 2012-05-18

Related Papers

Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6–23 months: phase III study (US/Puerto Rico)

Pediatric Research2026-03-06

P-662. Phase III, modified double-blind, randomized, parallel group, active-controlled, multi-center study of Meningococcal quadrivalent ACWY conjugated vaccine in infants from 6 through 23 months of age in the United States

Open Forum Infectious Diseases2025-01-29